1-2 of 2
Tanita Mason-Bright
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study

Shuo Ma, MD, Danielle M. Brander, MD, John F. Seymour, MBBS, PhD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, MBBS, Michael Y. Choi, MD, Constantine S. Tam, MBBS, Tanita Mason-Bright, Betty Prine, Wijith Munasinghe, PhD, Ming Zhu, PhD, Su Young Kim, MD, Rod A. Humerickhouse, MD PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 830.
https://doi.org/10.1182/blood.V126.23.830.830
Published: 2015
Journal Articles

Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Shuo Ma, MD PhD, Danielle M. Brander, MD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Constantine Tam, MD, Tanita Mason-Bright, Nikita K. Rudersdorf, Lori Gressick, BS, Jianning Yang, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD PhD, John F Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2014) 124 (21): 325.
https://doi.org/10.1182/blood.V124.21.325.325
Published: 2014